Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 Trial

What Was Tested

The paper reports a study of Abaloparatide and Teriparatide, published as a randomized controlled trial.

The researchers assessed the cardiovascular safety profile of abaloparatide.

Why It Was Studied

Abaloparatide is a US Food and Drug Administration-approved parathyroid hormone-related peptide analog for treatment of osteoporosis in postmenopausal women at high risk of fracture.

Who Took Part

According to the abstract, 2463 women were involved.

PubMed indexes the participants as middle-aged adults and older adults, women only.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Abaloparatide and who got the comparison, which limits bias.

A placebo (an inactive look-alike) gave the Abaloparatide group a baseline to be compared against.

The timeline in the abstract includes 18 months.

What Was Measured

Topics PubMed links to this paper include Blood Pressure, Bone Density, Bone Density Conservation Agents, Heart Failure, Heart Rate, Osteoporosis and Parathyroid Hormone-Related Protein.

Author keywords: MACE, abaloparatide and cardiovascular.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Abaloparatide and Teriparatide in 2463 women over 18 months.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2020 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Abaloparatide compound page and the Teriparatide compound page, all human trials.